86 related articles for article (PubMed ID: 22275452)
1. Comment on: Morden et al. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011;34:1965-1971.
Badrick EL; Buchan I; Renehan AG
Diabetes Care; 2012 Feb; 35(2):e15; author reply e16. PubMed ID: 22275452
[No Abstract] [Full Text] [Related]
2. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients.
Morden NE; Liu SK; Smith J; Mackenzie TA; Skinner J; Korc M
Diabetes Care; 2011 Sep; 34(9):1965-71. PubMed ID: 21775752
[TBL] [Abstract][Full Text] [Related]
3. Request for clarification from Ruiter et al regarding 'Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study'.
Carstensen B
Diabetologia; 2012 Mar; 55(3):857-8; author reply 859-60. PubMed ID: 22222505
[No Abstract] [Full Text] [Related]
4. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
Blin P; Lassalle R; Dureau-Pournin C; Ambrosino B; Bernard MA; Abouelfath A; Gin H; Le Jeunne C; Pariente A; Droz C; Moore N
Diabetologia; 2012 Mar; 55(3):644-53. PubMed ID: 22222504
[TBL] [Abstract][Full Text] [Related]
5. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
[TBL] [Abstract][Full Text] [Related]
6. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.
Fagot JP; Blotière PO; Ricordeau P; Weill A; Alla F; Allemand H
Diabetes Care; 2013 Feb; 36(2):294-301. PubMed ID: 22966091
[TBL] [Abstract][Full Text] [Related]
7. Insulin analogues and cancer risk: the emergence of second-generation studies.
Renehan AG
Diabetologia; 2012 Jan; 55(1):7-9. PubMed ID: 22033621
[TBL] [Abstract][Full Text] [Related]
8. Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies.
Wu JW; Filion KB; Azoulay L; Doll MK; Suissa S
Diabetes Care; 2016 Mar; 39(3):486-94. PubMed ID: 26740633
[TBL] [Abstract][Full Text] [Related]
9. Glargine safety, diabetes and cancer.
Rendell M; Akturk HK; Tella SH
Expert Opin Drug Saf; 2013 Mar; 12(2):247-63. PubMed ID: 23394441
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of insulin glargine on the risk of breast cancer.
Suissa S; Azoulay L; Dell'Aniello S; Evans M; Vora J; Pollak M
Diabetologia; 2011 Sep; 54(9):2254-62. PubMed ID: 21614572
[TBL] [Abstract][Full Text] [Related]
11. Risk of breast cancer in patients on long-acting insulin analogues in comparison with those on human insulin.
Kostev K
Diabetologia; 2012 May; 55(5):1554-5. PubMed ID: 22349110
[No Abstract] [Full Text] [Related]
12. Comment on Bordeleau et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366.
Zanders MM; Renehan AG; Bowker SL; Carstensen B; van de Poll-Franse LV; Johnson JA
Diabetes Care; 2014 Oct; 37(10):e221-2. PubMed ID: 25249682
[No Abstract] [Full Text] [Related]
13. Comment on Bordeleau et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366.
Suissa S; Azoulay L
Diabetes Care; 2014 Oct; 37(10):e216. PubMed ID: 25249678
[No Abstract] [Full Text] [Related]
14. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
15. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
[TBL] [Abstract][Full Text] [Related]
16. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.
Lind M; Fahlén M; Eliasson B; Odén A
Prim Care Diabetes; 2012 Apr; 6(1):53-9. PubMed ID: 22056422
[TBL] [Abstract][Full Text] [Related]
17. [No increased cancer risk with insulin analogues].
Jaursch-Hancke C
MMW Fortschr Med; 2013 May; 155(9):33. PubMed ID: 23951655
[No Abstract] [Full Text] [Related]
18. Carcinophobia in clinical research.
Ravid M
Pol Arch Med Wewn; 2012; 122 Suppl 1():65-7. PubMed ID: 23222198
[No Abstract] [Full Text] [Related]
19. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
Colhoun HM;
Diabetologia; 2009 Sep; 52(9):1755-65. PubMed ID: 19603149
[TBL] [Abstract][Full Text] [Related]
20. Risk of cancer in patients receiving insulin glargine.
Dawson LK; Hamilton LA
Am J Health Syst Pharm; 2010 Dec; 67(23):2025-31. PubMed ID: 21098374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
